By Sabela Ojea

The Food and Drug Administration said Tuesday that it approved Innoviva's Xacduro pneumonia treatment, which fights the Acinetobacter bacteria.

The federal regulator said Xacduro, which treats ventilator-associated bacterial pneumonia and hospital-acquired bacterial pneumonia, is hard to treat and poses a great threat to human health.

The FDA granted approval of Xacduro, administered by intravenous infusion, to Entasis Therapeutics, acquired by the pharma company Innoviva last year.

Write to Sabela Ojea at sabela.ojea@wsj.com

(END) Dow Jones Newswires

May 23, 2023 18:55 ET (22:55 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Grafico Azioni Innoviva (NASDAQ:INVA)
Storico
Da Mar 2025 a Mar 2025 Clicca qui per i Grafici di Innoviva
Grafico Azioni Innoviva (NASDAQ:INVA)
Storico
Da Mar 2024 a Mar 2025 Clicca qui per i Grafici di Innoviva